Executive summary: US Drug Patent 8,895,058 claims a specific oral weight-loss unit dosage combining immediate-release phentermine (about 2–8 mg) and controlled-release topiramate (about 15–50 mg) for BMI ≥25 kg/m², with a defined dose ratio (phentermine mg/day about 16% of topiramate mg/day) and a controlled-release pharmacokinetic profile (topiramate Cmax lower than non-controlled release with Tmax ~6–10 hours and no decrease in AUC). The claim set is tightly bound to a particular fixed-dose drug product design and exposure profile, which narrows infringement risk for generics that launch with different dose ratios, different release kinetics, or different topiramate PK outcomes. The patent’s enforceable scope also depends on whether “non-controlled release topiramate,” “AUC,” and “lower Cmax” are treated as measurable functional limitations during claim construction.
What is US Patent 8,895,058 and what does it claim for weight loss phentermine topiramate?
US 8,895,058 is directed to a unit dosage form for oral weight loss in adults with BMI ≥25 kg/m², combining:
- Immediate-release phentermine: 2–8 mg per unit dosage
- Controlled-release topiramate: 15–50 mg per unit dosage
- Dose ratio: phentermine mg/day is about 16% of topiramate mg/day
- PK constraints for the controlled-release topiramate:
- Tmax about 6–10 hours (with dependent claim ranges expanding to about 8–10 hours)
- controlled-release has a lower Cmax than non-controlled release topiramate
- controlled-release does not decrease total drug exposure (AUC)
The independent claim is supplemented by a broad patient-criteria ladder (overweight, obesity) and extensive dependent coverage of dose sub-ranges, specific dosage examples, form factor architectures (capsule and multi-segment tablet), and controlled-release bead coating/matrix formulation details.
How does claim scope map to infringement risk levers?
The infringement “decision points” are largely functional and design-based:
- Fixed-dose composition lock-in: phentermine 2–8 mg + topiramate 15–50 mg plus ~16% mg/day ratio
- Release-kinetics lock-in: topiramate Tmax ~6–10 hours and lower Cmax without AUC loss
- Formulation architecture lock-in (in dependent claims): bead design, capsule housing beads, delayed-release coating materials and ratios
- Packaging lock-in (claims 31–32): plural unit doses in sealed containers with administration instructions
If a generic competitor uses different dose strengths, different ratio, different PK profile, or a different release technology that does not reduce Cmax while preserving AUC, it may avoid these functional limitations.
What are the key independent-claim limitations in US 8,895,058 (phentermine IR + topiramate controlled release)?
Core composition limits
- Immediate-release phentermine unit dose: 2–8 mg
- Controlled-release topiramate unit dose: 15–50 mg
- Patient eligibility: BMI ≥25 kg/m²
- Ratio constraint: phentermine mg/day ≈ 16% of topiramate mg/day
Core PK functional limitations
- Controlled-release topiramate reaches Cmax at Tmax ~6–10 hours
- Controlled-release yields lower Cmax than non-controlled release topiramate
- Controlled-release does not decrease AUC
Practical scope effect: These are not merely “controlled-release” labels. They require that the product’s measured pharmacokinetics fall into defined behavioral outcomes relative to a comparator (“non-controlled release topiramate”) and preserve total exposure.
What do dependent claims 2–11 add about BMI ranges and obesity-associated conditions?
BMI tiering
- Claim 2: Overweight: BMI 25–29.9 kg/m²
- Claim 4: Obese: BMI ≥30 kg/m²
Condition associated with obesity
- Claims 3 and 5: subject has a condition associated with obesity (broad)
- Claims 6–7: a long enumerated list (diabetes, elevated fasting blood glucose, insulin resistance, impaired glucose tolerance, pulmonary hypertension, asthma, gallbladder disease, dyslipidemia, high cholesterol, triglycerides, osteoarthritis, reflux esophagitis, sleep apnea, menstrual irregularities, infertility, pregnancy complications, gout, hypertension/coronary disease/heart disease, muscular dystrophy, stroke/thrombotic stroke/DVT, migraines, metabolic disorders, lipid disorders, “Syndrome X,” multiple cancers, and cervical cancer)
- Claims 8–9: narrowed subset includes high blood pressure, high triglycerides, elevated fasting blood glucose, diabetes
- Claims 10–11: subject has at least two conditions selected from that narrowed subset
Practical scope effect: These limitations can provide an additional infringement path if a product is marketed/used for narrower phenotypes, but they also raise enforceability questions if the claim is strictly read as requiring those patient conditions.
How do dependent claims 12–20 narrow the phentermine/topiramate dose combinations?
Phentermine dose sub-range
- Claim 12: phentermine 2–5 mg
Topiramate dose sub-ranges
- Claim 13: topiramate 15–25 mg
- Claim 14: topiramate 17–23 mg
- Claims 15–16: corresponding ranges nested with claim 12
Specific fixed-dose examples
- Claim 17: phentermine 3.75 mg + topiramate 23 mg
- Claim 18: phentermine 3.75 mg corresponds to ~4.92 mg phentermine hydrochloride
- Claim 19: phentermine 7.5 mg + topiramate 46 mg
- Claim 20: phentermine hydrochloride ~9.84 mg corresponding to 7.5 mg base phentermine
Practical scope effect: If a generic launches at non-matching dose strengths or non-equivalent salts/assay equivalents, it may fall outside these dependent claim embodiments even if it practices the broad independent claim range.
What claims define topiramate controlled-release pharmacokinetics (Tmax/Cmax/AUC)?
Tmax ranges
- Claim 21: “substantially constant” topiramate blood level over 4–12 hours
- Claim 22: narrower 6–10 hours
- Claim 23: controlled-release topiramate Tmax ~8–10 hours
Cmax/AUC functional relationship
- Embedded in independent claim: controlled-release topiramate exhibits lower Cmax than non-controlled release topiramate without decreasing AUC.
Practical scope effect: This is the central design constraint that most generic formulation attempts must match. It also provides litigation leverage because it is measurable via pharmacokinetic bridging studies.
What formulation and dosage-form structures are protected by dependent claims 24–30?
Immediate-release phentermine beads
- Claim 24: immediate-release phentermine includes beads of inactive cores coated with immediate release phentermine
Capsule housing both bead populations
- Claim 25: capsule containing immediate release phentermine beads and controlled release topiramate beads
Controlled-release beads formulation architecture
- Claim 26: controlled release topiramate beads include:
- controlled release topiramate
- binder
- polymeric filler in a matrix core
- delayed release coating comprising ethyl cellulose and polyvinyl pyrrolidone
- Claim 27: polymeric filler includes microcrystalline cellulose
- Claim 28: binder includes methylcellulose
- Claim 29: ethyl cellulose to polyvinyl pyrrolidone weight ratio ~2.3:1
Tablet multi-segment alternative
- Claim 30: tablet with at least two discrete segments, one with immediate release phentermine and another with controlled release topiramate
Practical scope effect: These dependent claims can capture specific formulation “recipes.” A generic using different matrix-formers, binder systems, coating polymers, bead architectures, or segment designs may avoid infringement of these narrower embodiments while still risking independent-claim coverage if their overall PK and ratio limitations are met.
What packaging and method-use coverage exists in claims 31–32?
- Claim 31: packaged preparation with plural unit dosage forms in a sealed container plus instructions for oral administration to effect weight loss
- Claim 32: packaged preparation with each unit dose in discrete sealed housing plus instructions
Practical scope effect: These claims can support enforcement even where the active dosage form is similar, targeting specific commercialization and labeling/packaging practices for a fixed-dose product.
How strong is the patent estate around US 8,895,058 based on the claim design itself?
Without adding external patent numbers, the internal structure of US 8,895,058 shows a layered claim strategy:
- Independent claim on fixed-dose combination + PK outcomes
- Patient stratification dependent claims
- Dose strength dependent claims
- Functional PK dependent claims (Tmax behavior; AUC-preserving lower Cmax)
- Formulation recipe dependent claims (ethyl cellulose + PVP delayed release coating, binder and polymeric filler identity, filler/binder classes and ratios)
- Packaging dependent claims
Inference for litigation posture: The independent claim provides breadth across dosage-form architectures that satisfy the PK functional limitations. Dependent formulation claims provide additional hooks against specific manufacturing and release technologies. This structure typically supports both (a) argument that close formulations still infringe the independent claim if PK outcomes match and (b) narrower fallbacks if independent-claim construction is constrained.
What patent landscape issues matter most for competitors considering a generic or reformulated product?
1) Product design-around pathways
Most design-around attempts would target at least one of these elements:
- Dose ratio: move away from phentermine topiramate mg/day ~16%
- Dose strengths: avoid 3.75/23 mg and 7.5/46 mg equivalents
- PK profile: ensure topiramate Cmax is not “lower than non-controlled release” in the claimed comparative sense, or shift Tmax outside ~6–10 hours
- AUC: create a formulation that changes exposure such that AUC is “decreased” relative to the defined comparator condition
- Formulation materials: replace ethyl cellulose/PVP coating system with different polymers or coating ratio
2) Functional limitations are the main battleground
“Lower Cmax” and “no decrease in AUC” relative to “non-controlled release topiramate” can become dispute points:
- What comparator formulation is used for “non-controlled release topiramate”
- Whether AUC is assessed across a defined interval (AUC0-inf vs AUC0-t) in claim construction
- How much Cmax reduction is needed to meet “lower” in a meaningful quantitative manner
3) Formulation recipe claims increase discovery leverage
If the accused product uses ethyl cellulose and PVP in a delayed coating, plus methylcellulose binder and microcrystalline cellulose filler in the claimed weight ratio range, the dependent-claim alignment can become direct.
When do generics risk entry versus when can patent protection extend exclusivity?
This analysis is limited to the claims provided. A definitive “loss of exclusivity” timeline requires the patent’s actual filing date, USPTO patent term adjustments, and any applicable regulatory exclusivity or listed Orange Book exclusivity for the specific NDA/ANDA product. Those data are not included in the prompt. The claim scope itself indicates enforceability is strongest for products that match the fixed-dose ratio and controlled-release PK profile.
How does this patent’s scope compare to typical fixed-dose phentermine/topiramate product strategies?
Common strategic comparison axes
- Single extended-release topiramate vs beads/pellets-based delayed release
- IR phentermine beads vs blended IR in a tablet segment
- Coating polymer family (ethyl cellulose + PVP) vs alternative film formers
- Achieving a “lower Cmax but same AUC” profile via dose dumping prevention while preserving extent of absorption
Scope consequence
US 8,895,058 is structurally predisposed to be infringed by products designed to reproduce the same clinical PK objectives as an established fixed-dose combination: lower Cmax, delayed Tmax, and preserved AUC.
Key takeaways
- US 8,895,058 protects a specific fixed-dose phentermine/topiramate combination for BMI ≥25 kg/m² with a ~16% phentermine:topiramate mg/day ratio.
- The patent’s infringement center is functional PK: controlled-release topiramate with lower Cmax, Tmax ~6–10 hours, and no AUC decrease versus a comparator “non-controlled release topiramate.”
- Dependent claims expand coverage into dose-strength embodiments (including 3.75/23 mg and 7.5/46 mg examples), patient-condition subsets, capsule or segmented tablet designs, and detailed bead coating/matrix components (notably ethyl cellulose + PVP delayed release coating with defined ratio).
- For generic/reformulation efforts, the most plausible risk-reduction levers are to break the dose ratio, dose strengths, and especially the PK functional relationship (Cmax/Tmax/AUC), and to alter the coating/formulation system so it does not satisfy the dependent-claim recipe.
FAQs
1) What product attributes most directly determine infringement of claim 1 in US 8,895,058?
A fixed-dose oral unit meeting phentermine IR 2–8 mg, topiramate controlled-release 15–50 mg, phentermine:topiramate ~16% mg/day, and a topiramate PK profile with Tmax ~6–10 hours, lower Cmax, and no AUC decrease relative to non-controlled release.
2) Do claims 2–11 require that the patient actually has the listed obesity-associated conditions?
Yes, as written, those dependent claims require the subject to have the specified BMI tier and/or conditions enumerated in the claim sets.
3) How do claims 24–30 constrain dosage form architecture and coating chemistry?
They cover bead-based IR phentermine cores, capsule housing of IR and controlled-release beads, and controlled-release topiramate beads with a delayed release coating of ethyl cellulose and polyvinyl pyrrolidone, with binder and polymeric filler selections (methylcellulose; microcrystalline cellulose) and an approximate 2.3:1 weight ratio.
4) What is the significance of the comparator “non-controlled release topiramate” in the Cmax/AUC limitations?
It defines a functional comparison that ties claim scope to measurable PK outcomes versus a specified baseline formulation concept, which can drive claim construction and pharmacokinetic evidentiary disputes.
5) Can packaging and instructions claims (31–32) be infringed even if the dosage form is independently disputed?
Yes, claims 31–32 are separate claims directed to packaged plural unit dosage forms with administration instructions to effect weight loss, but infringement still generally depends on meeting the underlying “unit dosage form” limitations of claim 1 as incorporated into claim 31/32.
References
- US Patent 8,895,058 (claims as provided in the prompt).
